Welcome to our dedicated page for Sonnet Biotherapeutc Hldng SEC filings (Ticker: SONN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to decode immuno-oncology jargon buried in Sonnet BioTherapeutics Holdings Inc (SONN) disclosures? Each 10-K details FHAB platform breakthroughs, trial costs, and cash runway—yet stretches over 200 pages. Problem: extracting what really matters before the next data readout or capital raise takes hours.
Solution: Stock Titan’s AI lifts the fog around Sonnet BioTherapeutics SEC filings explained simply. Our engine delivers plain-English highlights the moment a document hits EDGAR, whether it’s a Sonnet BioTherapeutics quarterly earnings report 10-Q filing spelling out liquidity, or an Sonnet BioTherapeutics 8-K material events explained alerting you to new trial initiations. Need to monitor insider sentiment? Get instant pings on Sonnet BioTherapeutics Form 4 insider transactions real-time and drill into every Sonnet BioTherapeutics executive stock transactions Form 4—no more manual searches.
Our coverage spans every form: the Sonnet BioTherapeutics annual report 10-K simplified for R&D spend trends, Sonnet BioTherapeutics proxy statement executive compensation to see how milestones drive pay, plus S-1, 424B, and Section 16 filings. AI-powered summaries spotlight cash burn trajectories, FHAB patent updates, and pivotal trial endpoints, turning dense biotech language into actionable insights.
Whether you’re investigating Sonnet BioTherapeutics insider trading Form 4 transactions ahead of catalyst dates, running a Sonnet BioTherapeutics earnings report filing analysis, or simply understanding Sonnet BioTherapeutics SEC documents with AI, our real-time dashboard keeps you a step ahead—without wading through PDFs.
Insider transactions: Richard T. Kenney, identified as a Director and Chief Medical Officer of Sonnet BioTherapeutics Holdings, Inc. (SONN), received securities as partial consideration for a $200,000 convertible note. On 06/30/2025 he was issued warrants to purchase up to 86,505 common shares at a $1.156 exercise price. On 07/14/2025 he received warrants to purchase 320,000 common shares at $1.25 and 200 shares of Series 5 Preferred Stock initially convertible into 160,000 common shares at $1.25 per share. All instruments include a 4.99% beneficial ownership cap that prevents conversion or exercise beyond that threshold. The Form 4 is signed by Kenney on 08/21/2025.
Sonnet BioTherapeutics Holdings, Inc. reported continued clinical and corporate activity alongside significant losses and tight liquidity. The company had $321,297 in cash at June 30, 2025 and total assets of $2.06 million, against total liabilities of $5.10 million, producing a stockholders' deficit of $(3.05) million. For the nine months ended June 30, 2025 Sonnet reported a net loss of $10.43 million (three months: $3.78 million), and recognized $1.0 million of collaboration revenue related to the Alkem agreement.
The filing highlights clinical progress for lead programs: SON-1010 has been dosed in 99 people with partial responses at the highest dose and multiple combination cohorts (Roche combo and trabectedin cohort) underway, and SON-080 is partnered in India with Alkem. Management disclosed a July 2025 financing mix—convertible notes, preferred stock and warrant financings—and that warrant exercises in July 2025 generated $10.5 million, which together with prior raises they expect will fund operations into February 2026. The company states substantial doubt about its ability to continue as a going concern and expects to require additional financing.
FAQ
What is the current stock price of Sonnet Biotherapeutc Hldng (SONN)?
What is the market cap of Sonnet Biotherapeutc Hldng (SONN)?
